aTyr Pharma Inc (LIFE)
1.69
+0.03
(+1.81%)
USD |
NASDAQ |
May 07, 15:54
aTyr Pharma Research and Development Expense (Quarterly): 13.36M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 13.36M |
December 31, 2023 | 12.76M |
September 30, 2023 | 10.32M |
June 30, 2023 | 9.84M |
March 31, 2023 | 9.379M |
December 31, 2022 | 14.91M |
September 30, 2022 | 9.867M |
June 30, 2022 | 9.135M |
March 31, 2022 | 8.896M |
December 31, 2021 | 5.955M |
September 30, 2021 | 5.138M |
June 30, 2021 | 7.655M |
March 31, 2021 | 4.516M |
December 31, 2020 | 4.698M |
September 30, 2020 | 4.616M |
June 30, 2020 | 4.361M |
March 31, 2020 | 3.616M |
December 31, 2019 | 3.59M |
September 30, 2019 | 3.799M |
June 30, 2019 | 3.314M |
March 31, 2019 | 3.345M |
Date | Value |
---|---|
December 31, 2018 | 3.549M |
September 30, 2018 | 4.202M |
June 30, 2018 | 6.484M |
March 31, 2018 | 6.15M |
December 31, 2017 | 5.31M |
September 30, 2017 | 7.133M |
June 30, 2017 | 8.42M |
March 31, 2017 | 9.204M |
December 31, 2016 | 9.144M |
September 30, 2016 | 10.40M |
June 30, 2016 | 11.31M |
March 31, 2016 | 12.00M |
December 31, 2015 | 12.67M |
September 30, 2015 | 7.739M |
June 30, 2015 | 7.502M |
March 31, 2015 | 6.593M |
December 31, 2014 | 4.341M |
September 30, 2014 | 4.41M |
June 30, 2014 | 3.638M |
March 31, 2014 | 4.388M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.314M
Minimum
Jun 2019
14.91M
Maximum
Dec 2022
7.486M
Average
6.805M
Median
Research and Development Expense (Quarterly) Benchmarks
Vaxart Inc | 14.70M |
Allogene Therapeutics Inc | 54.66M |
AIM ImmunoTech Inc | 3.20M |
Protalix BioTherapeutics Inc | 3.102M |
Armata Pharmaceuticals Inc | 7.928M |